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Inhibition of Melanogenesis for Melanoma Therapy? 
To the Editor: 
Metastatic melanotic melanoma causes more deaths than any other 
skin tumor [1]. T his is primarily due to the inefficacy of conven-
tional chemotherapy and radiotherapy . Because intermediates of 
melanogenesis are melanocytotoxic [2], it has been proposed to 
destroy melanotic melanoma cell s by upregulation of melanogene-
sis and an increased supply of amino acid precursors (L-tyrosine, 
L-DOPA) or false precursors to melanin [3] . Though this strategy 
worked in il'l lIitro systems [2], we are not aware of any patient cured 
by such a protocol [4]. On the contrary, L-DOPA therapy in pa-
tients with Parkinson's disease is considered by some authors to be a 
risk factor for developing melanoma [5] . 
Almost 30 years ago, Demopoulos et al. [6,7] showed that inhibi-
tion of melanogenesis by restriction ofL-phenylalanine and L-tyro-
sine in the diet, or inhibition of tyrosinase, can slow if not reverse 
the progression of melanotic melanoma in humans and inhibit their 
growth in mice -observations later confirmed in rodent melanoma 
systems [8,9]. Thus, the inllillo situation appears to be the opposite of 
i ll vitro conditions: although dietary restriction of these amino acids 
may inhibit melanoma growth ill lI illO, increased supply of precur-
sors to melanin in vitro results in profound melanocytotoxicity [2]. 
This raises the question of what factors limit the effectiveness of 
melanocytotoxicity by melanogenesis i/1 "illo. 
The answer may lie in the role of L-DOPA, which is present in 
high concentration in melanotic melanomas [10], and can be re-
leased by melanoma cells together with other intermediates of mel-
anogenesis [11] . DOPA and its 3,4-dihydroxy analogs can inhibit 
phytohemagglutinin-stimulated DNA synthesis in lymphocytes 
from melanoma patients [12] and can dramaticall y inhibit lipopoly-
saccharides and concanavalin A- induced proliferation of human 
and mouse lymphocytes [13] . 
Melanogenically active cells may, therefore, be capable of inhib-
iting the local immune attack against malignant cells as well as the 
system.ic immune response via the production/release of L-DOPA 
and its metabolites. Intermediates of melanogenesis are detectable in 
serum of patients with melanotic melanoma [14]. T his may coun-
teract the efficacy of immunotherapy and may magnify the immu-
nosuppression present as a consequence of chemo- and radiother-
apy. Therefore, we support the concept of including strict dietary 
restriction of L-tyrosine and L-phenylalanine in melanoma therapy 
[6,7]' particularly when chemo- or immunotherapy are employed. 
Furthermore, because tyrosinase (the enzyme that oxidates tyros ine 
to DOPA and DOPA to DOPAquinone) is liberated after the de-
struction of melanotic melanoma cells [2], we propose to test 
w hether immunization with purified tyrosinase and treatment with 
inhibitors of tyrosinase is beneficial as an adjuvant therapy in the 
treatment of melanotic melanoma. 
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T-Cell Receptor Vp-Family Usage in Cutaneous Malignancies 
To the Editor: 
T-cell receptor (TCR) gene rearrangements constitute a unique 
marker of clonal ity in cutaneous lymphoid infiltrates. Consc-
quently, they are of particular value for the diagnosis and follow-up 
of patients w ith T-cell neoplasms [1 ,2]. Scvera l groups have applied 
polymerase chain reaction (PCR) - based techniques for the qualita-
tive and semiquantitative analysis of the TCR variable region usage 
[3- 6). 
In their article "T Cell Receptor V p-Family Usage in Primary 
Cutaneous and Primary N odal T-cell Non-Hodgkin's Lympho-
mas," Prcesman et al [6] report the amplification and semiquantita-
tive evaluation of TCR P rearrangcments in eight patients with 
mycosis fungoidcs (MF) or nodal non-Hodgkin'S lymphoma 
(NNHL) . For this purpose they amplified cDNA preparations from 
the respective lesions using a panel of 20 VfJ-region specific PCR 
primers. The PCR products were then separated on agarose gels 
stained with ethidium bromide, visualized under ultraviolet light 
and quantified by eyesight. Different levels of expression of TCR 
VfJ-regions were described by ass ignment to five groups ranging 
from non-detectable PCR product to PCR product signal as strong 
as the positive control. Furthermore, immunohistologic studies and 
gene rearrangement analysis by Southern blotting were performed. 
A varying intensity of the PCR product bands observed among 
hea lthy volunteers led to the conclusion that the primer set em-
ployed was "suitable to detect all 20 [V fJ-] farnilies." From the fact 
that three T-cell lines each expressed only one or two Vp-families, 
they deduced that the PCR primers "showed ... no cross-reacti-
vity" among the variolls V fJ regions. Moreover, the expression of 
one or two Vp-families in three advanced cases of MF and a "poly-
clonal" pattern in an early MF case was reported. The results gave 
VOL. 103, NO.5 NOVEMBER 1994 
no evidence for the preferential usage of particular Vp-families in 
eight patients with MF or NNHL. Finally, the authors discussed the 
value of their experimental design for the differentiation of malig-
nant from non-malignant T-cell proliferations, for the staging of 
malignant lymphomas, and for possible therapeutic approaches 
with monoclonal antibodies. 
Indeed, the semiquantitative analysis of T-cell receptor gene re-
arrangements can be a powerful tool for the investigation of malig-
nant and non-malignant T-cell proliferations but, in our opinion, 
there are some technical pitfalls that have to be considered. 
It is impossible to infer from the fact that there was amplification 
with all 20 Vp primer sets in healthy volunteers that the amplifica-
tion products were actuall y specific V p genes. It is also impossible to 
exclude cross reactivity between the 20 primer sets by examination 
of on ly three cell lines. 
One major problem for primer design within a multigene family 
is the variable level of homology between family members. This 
makes it difficult to design primers that are both sensitive and spe-
cific for all members of a given family. For example, the primers for 
Vp 8 as presented by Preesman and colleagues match to the Vp 
8.1- 8.4 genes, but not to Vp 8.5 and 8.6. The Vp 7 primers match 
only to the family member Vp7.1. The primers VP"12b" and "13" 
both match to the clone pi 4.24 (as described by Concannon et al [7]) 
and are therefore nonspecific. For this reason, other groups working 
in th is area have proved the specificity of their amplification by 
Southern blotting, oligomer extension reactions, or DNA sequenc-
ing [3-5] . 
An important determinant of the accuracy of semiquantitative 
PCR experiments is an equal amplification efficiency between the 
different primers . The melting temperatures of the PCR primers are 
important in this respect and should be grouped within a narrow 
range. The C p primer used by Preesman el al has a melting temper-
ature of77.2 °C, whereas the Vp 1 primer melts at 54.7"C (calcu-
lated accordin g to the nearest neighbor method [9]) . This mismatch 
of melting temperatures complicates the quantitative interpretation 
of the PCR results. To improve precision and accuracy, several 
other investigators [3 - 5] have coamplified a control TCR constant 
region segment as well as a unique ~CR Vp seg~ent in each reac-
tion tube. The coamplified segment III each tube IS used as a control 
for reaction variation and to determine the proportion of the respec-
tive Vp signal within the T-cell message pool. 
Another factor complicating Vp gene family semiquantitative 
analysis is the fact that the V{J families include varying numbers of 
members (e.g., Vp 1 has two members and Vp 6 has at least nine 
[10]) . Therefore, it is impossible to ~etermi~le the pr~va l en~e of 
specific V p fami ly utilization by visual IIlSpectlon of the 111tenSIty of 
a band ofPCR products. For example, if the usage ofV~ genes ill the 
general population is random, the signal for V{J 6 will always be 
more intense than the signal for Vp 1. 
The semiquantitative analysis of a multigene family such as 
TCR-VP by PCR is a challenging technical problem. It requires 
careful evaluation and optimization of several different amplifica-
tion conditions that influence the outcome of these experiments. 
Especially in cases of probable low tumor-cell density, such as earl y 
MF lesions, the above-mentioned technical problems complicate 
quantitative conclusions concerning tumor cell preva lence. Conse-
quently, it is difficult to use semiquantitative analysis of V{J gene 
family PCR products to detect malignant clones that constitute only 
a small proportion of aT-cell population. T his point has been made 
previously by Bahler et al [11] who showed that, when diluted by 
polyclonal T cel ls, a malignant T-cell clone must constitute at least 
- 10% of the total T -cell RNA or DNA to be detectable using a Vp 
gene family PCR assay. Therefore, such assays should be used 
cautiously to detect monoclonality in cases of possible low tumor-
cell density because of the increased risk of false negative resu lts as 
tumor-cell density decreases. 
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REPLY 
Our primer set to detect the different T-cell receptor (TC R) V{J 
gene families revealed highly reproducible results ll -3]. We also 
employed hybridization with an internal J{J-oligonucleotide probe 
on dried gels to obtain positive identification of the PCR products 
[1] . The bands observed coincide with those of ethidiumbromide 
sta ined gel [1] . T here was a very good correlation between the actual 
and calculated size of the PCR products (Hu, unpublished data). We 
also applied, for specificity reasons, sequencing of our PCR products 
in present experiments. So far we have not found discordant find-
ings between PCR V {J ana lysis and sequencing data [4] . For accurate 
specificity these investigations should be performed; therefore we 
ca n agree with Haffner et af on this point. However, the experi-
ments described were carried out in 1991 and indeed this fi eld 
progresses fast. 
We agree, as stated earlier [3 J, that the primer set does not cover 
all V{J gene fami lies or V{J gene fami ly members. On the other hand, 
however, we were able to detect the V {J gene usage in the four cases 
of primary nodal non-Hodgkin'S lymphoma (NHL) and the three 
patients with tumor-stage mycos is fungoides (MF) , which was the 
main interest of our study. So, despite the improvement of tech-
nique at present the conclusions still stand. Furthermore, we added 
four extra Vp oligonucleotides after this study, to incorporate more 
V{J families [4] . 
Extensive experiments were carried out to eva luate the optimal 
PCR conditions. The conditions of the method were chosen in such 
a way that all 20 V{J gene families could be assessed , irrespective of 
the dependency of PCR condi tions like nucleotide composition of 
the primers and the size of the fragment to be amplified [1] . T he use 
of the same conditions ofpCR amplification of each Vp gene fami ly 
may affect the detection of V{JI0 and V{J19. Generally the signal 
